NEXGEL, INC. — Form S-1
Filed August 20, 2026 · analyzed by the Registration Agent
S-1
▼ Likely negative
significance 72/100
What the filing says
NexGel filed an S-1 on August 20, 2026 to register resale of 15,252,337 common shares issuable upon conversion of convertible promissory notes totaling ~$11.4M issued April–May 2026 and in connection with the April 2026 Celularity acquisition. Notes convert at $0.60/share (subject to full-ratchet anti-dilution and automatic downward resets) and bear 10% interest. Company had $0.5M cash and $4.5M net loss for H1 2026, with substantial doubt about going-concern status. Registration covers only note conversions; warrant shares (5.8M+) not registered due to authorized share shortage. Stockholders rejected a 100M-share authorization in July 2026; a September 23, 2026 vote on 150M authorization is pending.
Why this rating
Major capital infusion ($11.4M ≈ 104% of $11M market cap) but highly dilutive with no floor on conversion price. Going-concern risk + authorized share shortage + insider exclusions create substantial execution/refinancing uncertainty.
Extracted items
- 2.02 results / earnings
- 7.01 Reg FD disclosure
See more from August 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.